[go: up one dir, main page]

ZA200601810B - Rage-related methods and compositions for treating glomerular injury - Google Patents

Rage-related methods and compositions for treating glomerular injury Download PDF

Info

Publication number
ZA200601810B
ZA200601810B ZA200601810A ZA200601810A ZA200601810B ZA 200601810 B ZA200601810 B ZA 200601810B ZA 200601810 A ZA200601810 A ZA 200601810A ZA 200601810 A ZA200601810 A ZA 200601810A ZA 200601810 B ZA200601810 B ZA 200601810B
Authority
ZA
South Africa
Prior art keywords
rage
subject
agent
article
ligand
Prior art date
Application number
ZA200601810A
Other languages
English (en)
Inventor
Ann Marie Schmidt
Vivette D'agati
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of ZA200601810B publication Critical patent/ZA200601810B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200601810A 2003-09-05 2004-09-03 Rage-related methods and compositions for treating glomerular injury ZA200601810B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50066303P 2003-09-05 2003-09-05

Publications (1)

Publication Number Publication Date
ZA200601810B true ZA200601810B (en) 2008-05-28

Family

ID=34272982

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200601810A ZA200601810B (en) 2003-09-05 2004-09-03 Rage-related methods and compositions for treating glomerular injury

Country Status (9)

Country Link
US (1) US20070014791A1 (fr)
EP (1) EP1660014A4 (fr)
JP (1) JP2007504247A (fr)
CN (1) CN1874782A (fr)
AU (1) AU2004270207A1 (fr)
CA (1) CA2536512A1 (fr)
IL (1) IL173868A0 (fr)
WO (1) WO2005023191A2 (fr)
ZA (1) ZA200601810B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020621A1 (fr) * 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Nouvelle proteine extracellulaire liant le peptide rage (en-rage), et utilisations correspondantes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
WO2004100890A2 (fr) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Procedes lies a la fonction rage g82s et compositions destinees au traitement de troubles inflammatoires
MX2007001559A (es) * 2004-08-03 2007-04-10 Transtech Pharma Inc Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso.
CA2575830A1 (fr) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Proteines de fusion recepteurs de type rage et procedes d'utilisation de celles-ci
BRPI0608401A2 (pt) * 2005-03-17 2010-11-16 Columbia Univ New York polipeptìdeo, composição farmacêutica, ácido nucleico, vetor de expressão, célula, métodos para inibir a ligação entre diáfano e o domìnio citoplasmático de rage, para identificar um agente que inibe a ligação entre o diáfano e o domìnio citoplasmático de rage, e, uso de um agente que inibe a ligação entre diáfano e o domìnio citoplasmático de rage
EP1963786B1 (fr) * 2005-12-23 2013-07-24 GCoder Systems AB Gabarit de positionnement
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
AU2007226863A1 (en) * 2006-03-21 2007-09-27 Wyeth Methods for preventing and treating amyloidogenic diseases
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (fr) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Protéines de fusion de l'immunoglobuline et procédés de fabrication
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
KR101603917B1 (ko) * 2008-05-09 2016-03-17 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
EP2421892A1 (fr) 2009-04-20 2012-02-29 Pfizer Inc. Contrôle de la glycosylation de protéines, compositions et méthodes associées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
WO2004100890A2 (fr) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Procedes lies a la fonction rage g82s et compositions destinees au traitement de troubles inflammatoires

Also Published As

Publication number Publication date
JP2007504247A (ja) 2007-03-01
US20070014791A1 (en) 2007-01-18
AU2004270207A1 (en) 2005-03-17
WO2005023191A3 (fr) 2006-06-08
IL173868A0 (en) 2006-07-05
WO2005023191A2 (fr) 2005-03-17
EP1660014A2 (fr) 2006-05-31
CN1874782A (zh) 2006-12-06
EP1660014A4 (fr) 2009-07-22
CA2536512A1 (fr) 2005-03-17

Similar Documents

Publication Publication Date Title
Tang et al. Extracellular vesicle–encapsulated IL-10 as novel nanotherapeutics against ischemic AKI
US20070014791A1 (en) Rage-related methods and copositions for treating glomerular injury
Huang et al. Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1/TGFβ1 signaling
Lim et al. Pharmacokinetic considerations in pediatric pharmacotherapy
Pereira et al. The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update
Prakash et al. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury
Nagai et al. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity
Reiniger et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse
Lindskog et al. Melanocortin 1 receptor agonists reduce proteinuria
Hartz et al. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy
Miyazaki et al. The effects of a selective inhibitor of c-Fos/activator protein-1 on endotoxin-induced acute kidney injury in mice
Lee et al. Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice
CA2761885A1 (fr) Procedes et compositions pour traiter un lupus
Peng et al. Targeting mast cells and basophils with anti-FcεRIα Fab-conjugated celastrol-loaded micelles suppresses allergic inflammation
WO2021058038A1 (fr) Utilisation d'une protéine cd200 et d'une protéine de fusion cd200 dans la préparation d'un médicament destiné au traitement du psoriasis
Akour et al. Receptor-mediated endocytosis across human placenta: emphasis on megalin
van Alem et al. Liposomal delivery improves the efficacy of prednisolone to attenuate renal inflammation in a mouse model of acute renal allograft rejection
Herrera et al. Paraproteinemic renal diseases that involve the tubulo-interstitium
LaRosa et al. Sepsis strategies in development
Luo et al. Ultrasound-responsive taurine lipid nanoparticles attenuate oxidative stress and promote macrophage polarization for diabetic wound healing
KR20220035860A (ko) 폐 섬유화 질환의 예방 또는 치료용 조성물
Kim et al. Glycoengineered stem cell-derived extracellular vesicles for targeted therapy of acute kidney injury
JP2002522398A (ja) 細胞外基質の過剰産生と蓄積に対し薬効を示す医薬組成物
Park et al. The protective effect of neutralizing high-mobility group box1 against chronic cyclosporine nephrotoxicity in mice
KR101730868B1 (ko) Ｖｓｉｇ４ 억제제를 유효성분으로 포함하는 난소암 예방 또는 치료용 약학조성물